Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)

The SELECT trial enrolled 17,604 patients with established cardiovascular disease and overweight or obesity but without diabetes — a design deliberately chosen to isolate the cardiovascular effects of semaglutide from any glucose-lowering benefit, since this population was specifically non-diabetic.

Semaglutide 2.4 mg weekly reduced the primary endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke from 8.0 percent to 6.5 percent — a 20 percent relative risk reduction (HR 0.80, p<0.001). All-cause mortality fell by 19 percent. Heart failure outcomes improved. Weight loss was 9.4 percent with semaglutide versus 0.9 percent with placebo. The drug was discontinued more often for GI side effects (16.6% vs 8.2%), but overall serious adverse events were actually lower in the semaglutide arm.

SELECT is a landmark trial that fundamentally changed the classification of GLP-1 receptor agonists. It established that these drugs reduce cardiovascular events in patients whose benefit mechanism cannot be glucose lowering — proving direct cardiovascular effects independent of antidiabetic action. Semaglutide and its class are now properly understood as cardiovascular drugs that also treat obesity and diabetes, not diabetes drugs with incidental cardiovascular benefits.

We rate the evidence strong, with exceptionally high clinical significance. A definitive large RCT expanding the evidence base for GLP-1 agonists to the full spectrum of patients with obesity and cardiovascular disease — regardless of diabetes status.